cmRNAbone · Project

3D-Printed Bone Repair Using Modified RNA Therapy for Trauma and Osteoporosis

healthPrototypeTRL 4Thin data (2/5)

Imagine your body could regrow bone the way a lizard regrows its tail — that's essentially what this project is chasing. The team designed tiny RNA molecules that tell your own cells to build new bone, blood vessels, and nerves right where a fracture happened. These RNA instructions are loaded into a custom 3D-printed scaffold that fits the exact shape of a patient's injury, like a biological cast that heals from the inside. The goal is to replace bone grafts and metal implants with a living, self-repairing solution.

By the numbers

consortium partners

countries involved (AT, CH, DE, ES, FR, NL)

industry partners in the consortium

SMEs participating

specific cmRNA types targeting bone, nerve, and blood vessel growth

36%

industry ratio in the consortium

The business problem

What needed solving

Bone fractures from trauma and osteoporosis affect millions of people, and current treatments — metal implants, bone grafts, synthetic fillers — often fail to truly regenerate living bone tissue. Patients face long recovery times, repeat surgeries, and implants that never fully integrate with natural bone. There is a massive unmet need for a therapy that triggers the body to regrow its own bone exactly where it's needed.

The solution

What was built

The project developed chemically modified RNA molecules loaded into lipid and polysaccharide nanoparticle vectors, embedded within a 3D-printable Hyaluronan-Calcium Phosphate biomaterial ink. Deliverables include characterization of the delivery vectors and formulation of a bioink that can be 3D-printed into patient-specific scaffolds that trigger bone, nerve, and blood vessel regeneration.

Audience

Who needs this

Orthopedic implant manufacturers looking for next-generation bone repair products3D bioprinting companies seeking high-value clinical applications for their platformsRNA therapeutics companies wanting to expand beyond vaccines into orthopedicsHospital networks and trauma centers dealing with complex fracture casesOsteoporosis treatment providers seeking regenerative alternatives to current drugs

Business applications

Who can put this to work

Orthopedic Medical Devices

enterprise

Target: Orthopedic implant and bone graft manufacturers

If you are an orthopedic device company dealing with the limitations of metal implants and synthetic bone grafts — this project developed a 3D-printable biomaterial ink loaded with 4 specific modified RNA types (sema3a, vegf, pdgf-bb, bmp7) that trigger the body's own bone, nerve, and blood vessel regeneration. The patient-specific 3D printing approach could let you offer personalized implants rather than off-the-shelf sizes. The consortium of 14 partners across 6 countries has already characterized the delivery vectors.

3D Bioprinting

mid-size

Target: Bioprinting equipment and bioink manufacturers

If you are a bioprinting company looking for high-value clinical applications — this project formulated a Hyaluronan-Calcium Phosphate biomaterial ink designed specifically for extrusion-based 3D bioprinting. The ink carries RNA-loaded nanoparticles built from lipids and polysaccharide nanocapsules, and it was engineered to have intrinsic bone-forming properties. With 5 industry partners in the consortium, the printing process was developed with manufacturing scalability in mind.

Pharmaceutical / RNA Therapeutics

enterprise

Target: RNA therapy and gene therapy companies

If you are a pharma company investing in RNA therapeutics beyond vaccines — this project extended chemically modified RNA technology into orthopedic regeneration, a largely untapped market. The team developed lipid and polysaccharide nanocapsule vectors for local RNA delivery to bone tissue, avoiding systemic side effects. With regulatory strategy and GMP-like production preparation already part of the project scope, this could accelerate your entry into musculoskeletal RNA therapies.

Frequently asked

Quick answers

What would it cost to license or adopt this technology?

The project data does not include specific licensing costs or pricing. The consortium includes 5 SMEs and 5 industry partners, suggesting commercial interest exists. Interested parties should contact the coordinator AO-Forschungsinstitut Davos to discuss licensing terms.

Can this be manufactured at industrial scale?

The project specifically designed the biomaterial ink for extrusion-based 3D bioprinting, which is inherently scalable once validated. GMP-like production preparation was included in the project scope across partner facilities. However, scaling from lab to clinical production still requires regulatory clearance and facility audits.

What is the IP situation and how can I license this?

With 14 consortium partners across 6 countries (AT, CH, DE, ES, FR, NL) and 5 industry partners, IP ownership is likely shared under the EU grant agreement. The coordinator AO-Forschungsinstitut Davos in Switzerland would be the first point of contact for IP discussions and licensing opportunities.

What regulatory approvals are needed?

The project included regulatory strategy development and preparation for a first-in-human clinical trial. As a combination product (RNA therapy + 3D-printed medical device), it would need to navigate both pharmaceutical and medical device regulatory pathways. Based on available project data, GMP-like production standards were being established but clinical trials had not yet started during the project period.

How far along is this technology?

The project ran from 2020 to 2024 and completed characterization of delivery vectors. The team conducted in vitro and in vivo testing and worked toward clinically relevant preclinical proof of concepts. Preparation for a first-in-human trial was underway, but based on available data the technology is still at the preclinical stage.

How does this integrate with existing orthopedic workflows?

The 3D-printing approach is designed to produce patient-specific scaffolds, which means it could integrate with existing CT/MRI imaging workflows already used in surgical planning. The extrusion-based bioprinting process was chosen for compatibility with established manufacturing methods. Hospital adoption would require new bioprinting equipment and trained personnel.

Consortium

Who built it

The cmRNAbone consortium is well-structured for eventual commercialization, with 14 partners spread across 6 European countries plus Switzerland. The 36% industry ratio (5 industry partners, 5 of which are SMEs) signals genuine commercial intent — these are not just academic labs publishing papers. The mix of 4 universities, 4 research organizations, and 5 industry players covers the full chain from RNA synthesis and vector development through 3D printing to regulatory strategy. The coordinator, AO-Forschungsinstitut Davos, is a well-known orthopedic research institute in Switzerland with strong ties to clinical practice. For a business looking to partner, the presence of multiple SMEs suggests the technology is being developed with market access in mind, not just scientific discovery.

AO-FORSCHUNGSINSTITUT DAVOSCoordinator · CH
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEthirdparty · FR
UNIVERSITAT BASELparticipant · CH
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBHparticipant · DE
UNIVERSITEIT MAASTRICHTparticipant · NL
QBEX GMBHparticipant · AT
ETHRIS GMBHparticipant · DE
FUNDACION IDONIALparticipant · ES
KUROS BIOSCIENCES BVparticipant · NL
UNIVERSITE DE BORDEAUXparticipant · FR
OZ BIOSCIENCES SASparticipant · FR
INSTITUT POLYTECHNIQUE DE BORDEAUXthirdparty · FR
FUNDACION CIDETECparticipant · ES
UNIVERSITATSSPITAL BASELthirdparty · CH

How to reach the team

AO-Forschungsinstitut Davos (Switzerland) — use SciTransfer's coordinator lookup service to get direct contact details

Order a report on this consortium See AO-FORSCHUNGSINSTITUT DAVOS profile →

Next steps

Talk to the team behind this work.

Want an introduction to the cmRNAbone team? SciTransfer can connect you with the right people and provide a detailed technology brief tailored to your business needs.

Order a report on this topic More in Health & Biomedical